|
|
Volumn 6, Issue 12, 2007, Pages 951-952
|
|
HIV combination products
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
ABACAVIR PLUS LAMIVUDINE;
ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE;
ANTIRETROVIRUS AGENT;
ATAZANAVIR;
CHEMOKINE RECEPTOR CCR5 ANTAGONIST;
EFAVIRENZ;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ELVITEGRAVIR;
EMTRICITABINE;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ENFUVIRTIDE;
GENERIC DRUG;
INTEGRASE INHIBITOR;
LAMIVUDINE;
LAMIVUDINE PLUS ZIDOVUDINE;
NEVIRAPINE;
PROTEINASE INHIBITOR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SAQUINAVIR;
TENOFOVIR DISOPROXIL;
ZIDOVUDINE;
ANTIVIRAL ACTIVITY;
ARTICLE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG CLASSIFICATION;
DRUG COST;
DRUG HYPERSENSITIVITY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SAFETY;
DRUG TOLERABILITY;
FRANCE;
GERMANY;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
ITALY;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
SPAIN;
UNITED KINGDOM;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 36749066612
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2448 Document Type: Article |
|
Times cited : (16)
|
|
References (3)
|
